Want to see UG full AI Analyst Report?
UG Stock Chart & Stats
$7.62
$0.63(8.27%)
At close: 4:00 PM EDT
$7.62
$0.63(8.27%)
Day’s Range― - ―
52-Week Range$5.58 - $8.78
Previous CloseN/A
Volume18.43K
Average Volume (3M)6.29K
Market Cap
$33.17M
Enterprise Value$31.52M
Total Cash (Recent Filing)$8.04M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)13.6
Beta0.28
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.26%
Share Statistics
EPS (TTM)0.52
Shares Outstanding4,594,319
10 Day Avg. Volume6,994
30 Day Avg. Volume6,291
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)2.52
Price to Sales (P/S)2.68
P/FCF Ratio14.83
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue2.88
Enterprise Value/Gross Profit6.18
Enterprise Value/Ebitda11.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero total debt provides durable financial flexibility, lowering bankruptcy and refinancing risk. This enables the company to fund working capital, absorb raw-material shocks, sustain dividends, and selectively invest in capacity or product qualification without relying on external leverage.
High-quality Cash ConversionConsistent conversion of earnings into cash supports long-term operational resiliency and capital allocation. Strong OCF/NI and near-par FCF imply internal funding for dividends, modest capex, and working capital, reducing dependence on external financing over a multi-month horizon.
Long, Rising Dividend Track RecordA multi-decade dividend history and a recent 20% raise signal disciplined capital returns and management confidence in cash generation. This institutionalizes shareholder returns, attracting income-focused customers and indicating board-level endorsement of financial stability.
Bears Say
Choppy Multi-year Revenue And Profit TrendIrregular revenue and profitability reduce visibility into future earnings and weaken long-term planning. Fluctuating top-line and margin trends can impede sustained investment in R&D or commercial expansion and make cash flow and dividend sustainability more sensitive to demand cycles.
Very Small Scale And Concentrated OperationsA tiny employee base suggests limited production scale, narrower product development bandwidth, and greater key-person or single-customer concentration risk. Small-scale operations can limit negotiating power with suppliers and constrain ability to absorb large contract losses or rapid volume spikes.
Volatile Year-to-year Cash Flow PatternIntermittent negative or weak free cash flow years introduce risk to recurring payouts and reinvestment plans. Even with strong recent conversion, volatility complicates budgeting and makes long-term commitments (R&D, capacity expansion, or sustained dividend increases) more exposed to cyclical swings.
United-Guardian News
UG FAQ
What was United-Guardian’s price range in the past 12 months?
United-Guardian lowest stock price was $5.58 and its highest was $8.78 in the past 12 months.
What is United-Guardian’s market cap?
United-Guardian’s market cap is $33.17M.
When is United-Guardian’s upcoming earnings report date?
United-Guardian’s upcoming earnings report date is Aug 07, 2026 which is in 5 days.
How were United-Guardian’s earnings last quarter?
United-Guardian released its earnings results on May 08, 2026. The company reported $0.178 earnings per share for the quarter, beating the consensus estimate of N/A by $0.178.
Is United-Guardian overvalued?
According to Wall Street analysts United-Guardian’s price is currently Overvalued.
Does United-Guardian pay dividends?
United-Guardian pays a Semiannually dividend of $0.3 which represents an annual dividend yield of 4.26%. See more information on United-Guardian dividends here
What is United-Guardian’s EPS estimate?
United-Guardian’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does United-Guardian have?
United-Guardian has 4,594,319 shares outstanding.
What happened to United-Guardian’s price movement after its last earnings report?
United-Guardian reported an EPS of $0.178 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.854%.
Which hedge fund is a major shareholder of United-Guardian?
Currently, no hedge funds are holding shares in UG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
United-Guardian Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.84%
12-Months-Change
Fundamentals
Return on Equity
4.26%
Trailing 12-Months
Asset Growth
-0.50%
Trailing 12-Months
Company Description
United-Guardian
United-Guardian, Inc., operating both domestically and globally, specializes in the development, production, and distribution of a diverse range of cosmetic raw materials, pharmaceutical solutions, medical-grade lubricants, and proprietary industrial chemicals. Its extensive cosmetic ingredients catalog includes the LUBRAJEL line of water-based moisturizing and lubricating gel formulations, featuring variants such as LUBRAJEL NATURAL (derived from natural sources), LUBRAJEL MARINE, and LUBRASIL II SB (a silicone-infused LUBRAJEL formulation). Other key offerings in this category are LUBRAJEL II XD; B-122, a powdered lubricant suitable for pressed powders, eyeliners, blushes, and industrial uses; KLENSOFT, a surfactant for shampoos, shower gels, and makeup removers; and ORCHID COMPLEX, an oil-soluble base for skin creams, lotions, and cleansers. For medical applications, United-Guardian provides lubricants like LUBRAJEL RR and RC, which are water-based gels specifically designed for urinary catheters. LUBRAJEL MG serves to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices. The company also offers LUBRAJEL LC and LUBRAJEL FA, specialized LUBRAJEL formulations tailored for oral care, alongside LUBRAJEL FLUID for lubricating various water-soluble products. The pharmaceutical portfolio features RENACIDIN, a prescription medication for preventing and dissolving calcifications in urethral catheters and the urinary bladder. Also included is CLORPACTIN WCS-90, an antimicrobial agent effective against infections in the urinary bladder, localized peritoneal infections, and infections affecting the eyes, ears, nose, throat, and sinuses. Industrial products comprise DESELEX, a sequestering and chelating agent vital for detergent manufacturing, and THOROCLENS, a powerful chlorine-based industrial cleaning solution. The firm also dedicates resources to research and development, primarily focusing on advancing cosmetic ingredients. Products are brought to market through a robust network of marketing partners, distributors, and wholesalers. Established in 1942, United-Guardian maintains its headquarters in Hauppauge, New York.
Technical Analysis
Church & Dwight
―
Clorox
―
Colgate-Palmolive
―
Honest Company
―
Grove Collaborative Holdings
―
Ownership Overview
22.45% Insiders
6.86% Mutual Funds
1.10% Other Institutional Investors
65.44% Public Companies and
Individual Investors